Health Care Professional Resources
The Healing NET Foundation supports the education and training of health care professionals across the United States so they can provide the comprehensive care so essential for NET patients. See below for a variety of resources available to you, the health care professional, to aide you in learning more about NETs treatments.
The Healing NET Foundation created a NET Primer for health care professionals that outlines the fundamental concepts of neuroendocrine tumors. This brochure provides a basic description of the disease, some recommendations on how to recognize, diagnose, and treat it, and some pearls in patient care.
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system.
Organizations & Conferences
- North American Neuroendocrine Tumor Society (NANETS) - www.nanets.net
- NANETS 2018 Grants--applications due June 13, 2018. Click here to see the full array of grants available. ,
- NANETS Conference 2015 Reports
NETTER -1 Phase III Trial results on Lutathera is published in New England Journal of Medicine
Saint-Genis-Pouilly, France – January 12, 2017 – Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the New England Journal of Medicine published the results of the NETTER-1 Phase III study evaluating efficacy and safety of Lutathera® (lutetium-177 dotatate), an investigational drug, in patients with advanced, progressive somatostatin receptor-positive midgut neuroendocrine tumors (“NETs”).
To read more click here
New Drug in Development Shows Improved Progression-Free Survival for Patients with Advanced Metastatic Midgut Neuroendocrine Tumors
A new therapy in development for the treatment of midgut neuroendocrine tumors, a rare type of cancer that occurs in the small intestine and colon, shows improved progression-free survival and response rates for patients with advanced disease. Results of the international phase 3 clinical trial of lutetium-177 (177Lu)-Dotatate compared to high-dose octreotide LAR were published in the Jan. 12 issue of the New England Journal of Medicine.
To read more click here
The 2nd Annual HNF International NET Summit will be Feb 21-23 in Beaver Creek, CO. Last year more than 30 faculty convened with NET experts from across the United States and Europe to begin a conversation on the intricacies and challenges in caring for patients with neuroendocrine cancer and carcinoid syndrome. This year's Summit will focus on "Unmet Needs in the NET Community" and more than 40 faculty are expected, from various disciplines including endocrinology, gastroenterology, oncology, surgery, basic science, radiology, and cardiology. The faculty is by invitation from the Summit Scientific Advisory Committee. Sponsors include the medical industry, pharmaceutical industry, patient advocacy groups, and a Prospectus on the Summit can be obtained by reaching out to AAdair@the-lynx-group.com or firstname.lastname@example.org.